Dao Tun advised Quimatryx in a 92 million dollars licensing deal for a cancer drug  

Therwil/Baselland, Switzerland, April 05, 2022 - Dao Tun GmbH advised the company Quimatryx (based in San Sebastián, Spain) for licensing a cancer drug for 92 million dollars with the company HiDiamond. HiDiamond will develop the entire regulatory preclinical phase and conduct the clinical trials to be able to treat patients in China. 

“We are very pleased to have been able to support Quimatryx in finding a suitable partner and to accompany the team from the beginning to the closing of the deal. We look forward to seeing the results of the synergies between European innovation and Chinese acceleration and expansion.”commented Tianke Wang, PhD, CEO of Dao Tun

For more information, please visit